Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

SARS-CoV-2 alpha variant: is it really more deadly? A population level observational study

View ORCID ProfileCandace Makeda Moore, View ORCID ProfileRuslan Sergienko, View ORCID ProfileRonen Arbel
doi: https://doi.org/10.1101/2021.08.17.21262167
Candace Makeda Moore
1Maximizing Health Outcomes Research Lab, Sapir College, Sderot, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Candace Makeda Moore
  • For correspondence: doctormakeda@gmail.com
Ruslan Sergienko
2Department of Health Policy and Management, Ben-Gurion University of the Negev, Beer Sheva, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ruslan Sergienko
Ronen Arbel
1Maximizing Health Outcomes Research Lab, Sapir College, Sderot, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ronen Arbel
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background In 2021 a new variant of SARS-CoV-2, which came to be called the alpha variant, spread around the world. There were conflicting reports on this COVID-19 variant strain’s potentially increased lethality. In Israel, this strain became predominant in a very short time period.

Methods COVID-19 mortality and case fatality rates were examined in Israel in terms of weekly and cumulative numbers.

Results COVID-19 case fatality rates in Israel rose quickly at the beginning of the pandemic and peaked in May 2020. The highest crude mortality came later in the second and third waves, but case the case fatality rates did not rise in 2021 with the increasing dominance of the alpha variant.

Conclusions Based on the results of examining case-fatality and mortality rates, we concluded that while the alpha variant of the virus raised mortality, in line with the fact that it is more infectious than wild-type, once this strain was caught by patients in Israel, it was not more likely to kill them than the original strain

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The MaxCor lab is the recipient of funds from the Israel Institute for Health Policy Research with grant number 2020/442. The funder had no direct role in the development of the report or analysis and no involvement in the publication process.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This research was purely observational based on publicly available datasets and published research, and therefore did not require an IRB or oversight body approval.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data for this article was made from the original publically available data of the Israel Ministry of Health online, and is cited. In some cases, data has been processed from this original data.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted August 18, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
SARS-CoV-2 alpha variant: is it really more deadly? A population level observational study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
SARS-CoV-2 alpha variant: is it really more deadly? A population level observational study
Candace Makeda Moore, Ruslan Sergienko, Ronen Arbel
medRxiv 2021.08.17.21262167; doi: https://doi.org/10.1101/2021.08.17.21262167
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
SARS-CoV-2 alpha variant: is it really more deadly? A population level observational study
Candace Makeda Moore, Ruslan Sergienko, Ronen Arbel
medRxiv 2021.08.17.21262167; doi: https://doi.org/10.1101/2021.08.17.21262167

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (214)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1091)
  • Dentistry and Oral Medicine (194)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (497)
  • Epidemiology (9747)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2299)
  • Geriatric Medicine (221)
  • Health Economics (461)
  • Health Informatics (1548)
  • Health Policy (729)
  • Health Systems and Quality Improvement (600)
  • Hematology (236)
  • HIV/AIDS (500)
  • Infectious Diseases (except HIV/AIDS) (11623)
  • Intensive Care and Critical Care Medicine (615)
  • Medical Education (236)
  • Medical Ethics (67)
  • Nephrology (256)
  • Neurology (2137)
  • Nursing (133)
  • Nutrition (332)
  • Obstetrics and Gynecology (424)
  • Occupational and Environmental Health (516)
  • Oncology (1171)
  • Ophthalmology (363)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (145)
  • Palliative Medicine (50)
  • Pathology (308)
  • Pediatrics (693)
  • Pharmacology and Therapeutics (298)
  • Primary Care Research (265)
  • Psychiatry and Clinical Psychology (2168)
  • Public and Global Health (4640)
  • Radiology and Imaging (775)
  • Rehabilitation Medicine and Physical Therapy (451)
  • Respiratory Medicine (622)
  • Rheumatology (273)
  • Sexual and Reproductive Health (224)
  • Sports Medicine (208)
  • Surgery (250)
  • Toxicology (42)
  • Transplantation (120)
  • Urology (94)